Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
AtriCure, Inc. Chief Technical Officer Salvatore Privitera reported equity compensation activity involving company common stock. He acquired 30,390 shares on March 1, 2026 through a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares on the same date from the vesting and release of a Performance Share Award under the same plan after company performance goals and service requirements were met. To cover tax withholding obligations related to vesting and release of prior awards, he transferred 13,127 shares back to the company at $31.26 per share, and directly owned 158,048 shares after these transactions.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported equity awards and related tax withholding transactions in company common stock. He acquired 30,390 shares through a restricted stock award under the 2023 Stock Incentive Plan, with one third vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares from the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from earlier restricted or performance share vesting, he transferred 15,585 shares back to AtriCure at a price of $31.26 per share.
AtriCure, Inc. reported equity award activity for Chief Financial Officer Angela L. Wirick. On March 1, 2026, she acquired 39,987 shares of common stock through a restricted stock award under the 2023 Stock Incentive Plan, which will vest in three equal annual installments. She also acquired 23,101 shares from the vesting of a performance share award after company performance goals and service requirements were met. To cover tax withholding from these vestings, she disposed of 22,965 shares back to the company at $31.26 per share, leaving her with 204,893 directly owned shares of common stock.
AtriCure, Inc. Chief Operating Officer Douglas J. Seith reported equity compensation and related tax withholding in company stock. On March 1, 2026, he received 42,386 shares of common stock as a restricted stock award that vests in three equal annual installments. He also acquired 25,532 shares through the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from these vestings, he transferred 22,948 shares back to the company at $31.26 per share. Following these transactions, he directly owned 229,340 shares of AtriCure common stock.
AtriCure, Inc.’s Chief Legal Officer, Karl S. Dahlquist, reported equity compensation and related tax withholding transactions in company common stock. He acquired 27,991 shares through a restricted stock award and 15,198 shares through the vesting of a performance share award under the 2023 Stock Incentive Plan.
According to the filing, one third of the restricted stock will vest on each of the first, second, and third anniversaries of the grant date. The performance share award vested after company performance goals and service requirements were met.
Dahlquist also disposed of 15,687 shares at a price of $31.26 per share by transferring them back to the company to satisfy tax withholding obligations arising from the vesting and release of earlier restricted stock or performance share awards.
AtriCure, Inc. develops and sells medical devices for surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post‑operative pain control. Its products are used in open‑heart, minimally invasive, and hybrid procedures, and are sold mainly through a direct sales force in the U.S. and key international markets.
The company’s portfolio includes Isolator Synergy and EnCompass RF clamps, EPi‑Sense hybrid ablation systems, AtriClip LAA exclusion devices, and cryoICE/cryoSPHERE/cryoXT probes for Cryo Nerve Block pain therapy. AtriCure supports these products with extensive clinical trials such as CONVERGE, LeAAPS, BoxX‑NoAF, HEAL‑IST and ICE‑AFIB, and invests heavily in physician training and education.
AtriCure highlights large underpenetrated markets in Afib surgery, LAA exclusion, and non‑opioid pain management, while noting competitive, regulatory, reimbursement and execution risks. As of June 30, 2025, non‑affiliate common stock held a market value of about $1,571.5 million, with 49,809,901 shares outstanding as of February 12, 2026.
AtriCure, Inc. reported strong growth for the fourth quarter and full year 2025 while moving toward sustained profitability. Fourth quarter 2025 revenue was $140.5 million, up 13.1% year over year, with net income of $1.8 million and adjusted EBITDA of $19.9 million. Full year 2025 revenue reached $534.5 million, an increase of 14.9%, and gross margin improved to 75.0%. The company narrowed its net loss to $11.4 million while nearly doubling adjusted EBITDA to $61.8 million. Management projects 2026 revenue of $600–$610 million, full year positive net income, and adjusted EBITDA of $80–$82 million, with expected adjusted EPS between $0.09 and $0.15 and GAAP EPS between $0.00 and $0.04.
Hood River Capital Management LLC filed Amendment No. 2 to a Schedule 13G reporting its beneficial ownership of AtriCure, Inc. common stock. The firm reports holding 3,096,611 shares, representing 6.23% of the outstanding common stock as of the event date.
Hood River discloses sole power to dispose of these 3,096,611 shares but no power to vote them. It certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of AtriCure.
AtriCure, Inc. entered into a First Amendment to its credit agreement with JPMorgan Chase Bank and other lenders, extending the term of its asset-based revolving credit facility by three years. The amended credit agreement maintains an asset-based revolving credit facility of up to $125 million, with the option to increase commitments by up to $40 million, for a potential total of $165 million. A portion of the facility not exceeding $5 million is available for letters of credit, and swingline loans may be advanced at the Administrative Agent’s discretion. The amendment also reduces the overall interest rate on loans under the facility and removes the minimum utilization financial covenant. The facility is secured by a first priority security interest in substantially all borrower assets and is guaranteed by the company and its material domestic subsidiaries, and it will be used to finance working capital and general corporate purposes.
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported a charitable gift of 4,000 shares of AtriCure common stock on 12/10/2025. The transfer is coded as a gift and recorded at a price of $0, reflecting that no consideration was received for the donation. After this transaction, he beneficially owns 687,377 shares directly, with an additional 9,310 shares held by his children and 2,250 shares held by his parents, which he reports as indirect holdings while disclaiming beneficial ownership except for his pecuniary interest.